Roche Pipeline Will Make Up for Sales Loss, CEO Says
(Bloomberg) -- Roche Holding AG expects to maintain its leading position in cancer drugs as its product pipeline will plug the gap in sales resulting from cheaper copycats equivalent to 10 billion francs ($10 billion) in revenue by 2020, CEO Severin Schwan told Swiss newspaper NZZ am Sonntag.
“We have five to six cancer drugs with multi-billion revenue potential. In addition to multiple sclerosis drugs, there are also new drugs for hemophilia and neurological diseases. In sum they will replace the lost sales,” Schwan is quoted as saying in an extract of an article to be published on Sunday.
Schwan said staffing levels in Switzerland will remain stable despite the loss in sales. “Efficiency gains are better achieved through steady adjustments than through occasional big restructuring programs,” he said, adding that Roche was adapting its sales and distribution operations to reflect changed in its revenue mix and new products.
The trend of moving routine jobs out of Switzerland will continue, while more complex roles will remain in the country.
To contact the reporter on this story: Jan Dahinten in Zurich at jdahinten@bloomberg.net
To contact the editors responsible for this story: Jan Dahinten at jdahinten@bloomberg.net, James Ludden
©2018 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
